NAS:NBSE (USA) Also trade in: Germany

NeuBase Therapeutics Inc

$ 4.61 -0.04 (-0.86%)
Volume: 30,109 Avg Vol (1m): 207,061
Market Cap $: 78.69 Mil Enterprise Value $: 77.27 Mil
P/E (TTM): 0.00 P/B: 1.64
Earnings Power Value 1.18
Net Current Asset Value 0.28
Tangible Book 0.29
Projected FCF -48.68
Median P/S Value 0
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 8/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt No Debt
Cash-To-Debt range over the past 10 years
Min: 0.02, Med: 142.58, Max: 10000
Current: 10000
0.02
10000
Interest Coverage No Debt
N/A
Piotroski F-Score 2
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 39.23
DISTRESS
GREY
SAFE
WACC vs ROIC %
ROIC -52.49%
WACC 4.07%

Profitability & Growth : 3/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
ROE % -86.47
ROE range over the past 10 years
Min: -267.49, Med: -77.43, Max: 427.71
Current: -86.47
-267.49
427.71
ROA % -81.18
ROA range over the past 10 years
Min: -361.2, Med: -67.45, Max: 37.38
Current: -81.18
-361.2
37.38
ROC (Joel Greenblatt) % -28353.33
ROC (Joel Greenblatt) range over the past 10 years
Min: -28353.33, Med: -13616.42, Max: 4300
Current: -28353.33
-28353.33
4300
3-Year Total EBITDA Growth Rate 21.30
3-Year EBITDA Growth Rate range over the past 10 years
Min: 0, Med: -81.5, Max: 37.3
Current: 37.3
0
37.3
3-Year EPS w/o NRI Growth Rate 24.80
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: -63.8, Max: 24.8
Current: 24.8
0
24.8

Ratios

Current vs industry vs history
PB Ratio 1.64
PB Ratio range over the past 10 years
Min: 0.27, Med: 134, Max: 1310
Current: 1.64
0.27
1310
EV-to-EBIT -18.17
EV-to-EBIT range over the past 10 years
Min: -108.1, Med: -10.95, Max: 0
Current: -18.17
-108.1
0
EV-to-EBITDA -22.24
EV-to-EBITDA range over the past 10 years
Min: -108.1, Med: -10.95, Max: 0
Current: -22.24
-108.1
0
Current Ratio 2.07
Current Ratio range over the past 10 years
Min: 0.04, Med: 2.8, Max: 24.65
Current: 2.07
0.04
24.65
Quick Ratio 2.07
Quick Ratio range over the past 10 years
Min: 0.04, Med: 2.8, Max: 24.65
Current: 2.07
0.04
24.65

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -22.90
3-Year Share Buyback Rate range over the past 10 years
Min: -106.1, Med: -21.4, Max: 0
Current: -22.9
-106.1
0

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 15.90
Price-to-Tangible-Book range over the past 10 years
Min: 1.79, Med: 13.08, Max: 1500
Current: 15.9
1.79
1500
Earnings Yield (Joel Greenblatt) % -5.50
Earnings Yield (Greenblatt) range over the past 10 years
Min: -6532.97, Med: -9.15, Max: -0.9
Current: -5.5
-6532.97
-0.9

» NBSE's 30-Y Financials

Financials (Next Earnings Date: 2019-11-15)

» Interactive Chart

Peter Lynch Chart

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:NBSE

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare TSE:6090 NAS:CWBR ASX:MDC OSTO:MVIR B NAS:UMRX XKRX:203400 NAS:HOTH TSE:4583 XPAR:OSE XKRX:002720 ASX:IMU NAS:ARAV XSWX:POLN NAS:SURF NAS:SNSS TSE:7776 NAS:MRNS XKRX:215380 XKRX:041910 OSTO:INDEX
Traded in other countries O7PA.Germany
Address 800 Third Avenue, 11th Floor, New York, NY, USA, 10022
Ohr Pharmaceutical Inc is a US-based pharmaceutical company which focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. The lead product of the company is topical Squalamine is a novel therapeutic product which provides non-invasive therapy to improve visual outcomes. Its product pipeline includes SQUALAMINE LACTATE OPHTHALMIC SOLUTION 0.2%, SKS sustained release ocular drug delivery platform technology, Animal Model for Dry-AMD, and Non-Ophthalmology Assets.

More Statistics

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 2
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N